USANA Health Sciences Projects 23% Revenue Growth, Trades at EV/EBITDA 2.67
USANA Health Sciences is shifting from its declining MLM core to focus on high-growth Hiya and Rise Wellness brands, with Hiya’s Disney collaboration and subscription model driving a projected 23% revenue increase. The stock trades at an EV/EBITDA multiple of 2.67 and carries a 2026 target price of $24.33, 25% above current levels.
1. Strategic Pivot to Hiya and Rise Wellness
USANA has reoriented its portfolio away from its traditional multi-level marketing business toward branded consumer health products. Management highlights Hiya and Rise Wellness as core growth engines, leveraging differentiated products and new distribution channels to offset declines in its legacy segment.
2. Hiya Disney Collaboration and Subscription Model
Hiya’s partnership with Disney has expanded brand visibility and is supported by a subscription framework designed to drive recurring revenue. This model underpins USANA’s forecasted 23% top-line growth by enhancing customer retention and enabling predictable monthly sales.
3. Valuation Metrics and Price Target
At an EV/EBITDA multiple of 2.67, USANA trades well below peers, reflecting a valuation discount. Analysts project a 2026 target price of $24.33, implying 25% upside, based on earnings revisions and anticipated brand momentum.